Biomea Fusion (BMEA) News
NASDAQ: BMEAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
0.5744-0.014 (-2.38%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
BMEA news summary
We found 6 recent headlines mentioning Biomea Fusion (BMEA): 0 in the past week and 2 in the past 30 days, most often from GlobeNewswire, Nasdaq. For price context, BMEA is down 2.38% at $0.5744. The most recent story, "Biomea Fusion to Participate in Upcoming Investor Conferences", was published by GlobeNewswire on Nov 12, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Biomea Fusion headlines
- Biomea Fusion to Participate in Upcoming Investor ConferencesSAN CARLOS, Calif., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company, today announced that members of its management team…GlobeNewswire
- Biomea Fusion Reports Third Quarter 2026 Financial Results and Corporate HighlightsSAN CARLOS, Calif., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today reported…GlobeNewswire
- Weekly Buzz: RHHBY, TEVA Win FDA Nod; MLAB, GSK Cut Jobs; AZN, VIR Deals; KRYS, ABBV Report Data(RTTNews) - This week's healthcare roundup brings a series of regulatory wins, corporate restructuring, billion-dollar deals and clinical milestones.NasdaqABBV, ANL, ARWR, AZN
- Biomea Reports Phase 1 Weight-Loss Data For Oral GLP-1 Candidate BMF-650; Shares Fall(RTTNews) - Biomea Fusion Inc. (BMEA) reported Phase 1 results for BMF-650, its investigational oral glucagon-like peptide-1 (GLP-1) receptor agonist being developed for obesity and metabolic…NasdaqBMEA, ET
- Biomea Fusion Announces Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor AgonistSAN CARLOS, Calif., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company, today announced Phase 1 GLP-131…GlobeNewswire
- Biomea Fusion to Announce Phase I Results for BMF-650, Its Next-Generation Oral Small-Molecule GLP-1 Receptor AgonistCompany to host conference call and webcast on October 13, 2026, at 4:30 p.m. ET (1:30 p.m. PT) Company to host conference call and webcast on October 13, 2026, at 4:30 p.m. ET (1:30 p.m. PT)GlobeNewswire